A COMPARATIVE STUDY ON CANCER DETECTION ACROSS DIFFERENT STAGES OF CARCINOMA DEVELOPMENT USING MOLECULAR BIOLOGY TECHNIQUES
DOI:
https://doi.org/10.69980/2c2v2c56Keywords:
Carcinoma Detection, Molecular Biology Techniques, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Biomarker Analysis, Circulating Tumor DNA, Molecular Diagnostics, Personalized Cancer TherapyAbstract
Carcinoma, a malignancy arising from epithelial cells, is the most common cancer globally and is linked to significant morbidity and mortality, especially due to late diagnosis and disease advancement. The goal of this study is to compare the usefulness of molecular biology approaches including polymerase chain reaction (PCR), next-generation sequencing (NGS), and biomarker analysis in finding cancer at different stages of development. The study concentrates on evaluating stage-specific diagnostic accuracy, expression patterns of molecular markers, and the sensitivity and specificity of different diagnostic methodologies. The results show that PCR-based methods, notably droplet digital PCR, are very good at finding known genetic alterations and circulating tumor DNA in the early stages of cancer. NGS offers extensive genomic profiling and is essential for detecting new mutations, tumor heterogeneity, and drug resistance, rendering it particularly successful in intermediate and later stages. Biomarker analysis, which looks at proteins, microRNAs, and epigenetic markers, is a way to screen for diseases, keep an eye on them, and figure out how likely they are to get better without having to do any intrusive tests. The combination of various molecular diagnostic technologies greatly improves the accuracy of detection and helps with planning individualized treatment. Nevertheless, significant obstacles to wider clinical adoption persist, including prohibitive costs, the necessity for extensive technical proficiency, and the unpredictability in biomarker expression. The study's conclusion is that a multi-modal diagnostic technique that combines PCR, NGS, and biomarker analysis is a promising way to improve early detection, treatment decisions, and survival rates in people with carcinoma.
References
1.Benz, E. J. (2017). The Jeremiah Metzger Lecture Cancer in the Twenty-First Century: An Inside View from an Outsider. Transactions of the American Clinical and Climatological Association.
2.Berchuck, A., Iversen, E. S., Lancaster, J. M., Pittman, J., Luo, J., Lee, P., Murphy, S., Dressman, H. K., Febbo, P. G., West, M., Nevins, J. R., & Marks, J. R. (2005). Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers. Clinical Cancer Research, 11(10), 3686–3696. https://doi.org/10.1158/1078-0432.CCR-04-2398
3.Bestvina, C. M., Waters, D., Morrison, L., Emond, B., Lafeuille, M. H., Hilts, A., Mujwara, D., Lefebvre, P., He, A., & Vanderpoel, J. (2024). Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer. Journal of Managed Care and Specialty Pharmacy . https://doi.org/10.18553/jmcp.2024.24137
4.Brown, J. S., Amend, S. R., Austin, R. H., Gatenby, R. A., Hammarlund, E. U., & Pienta, K. J. (2023). Updating the Definition of Cancer. Molecular Cancer Research, 21(11), 1142–1147. https://doi.org/10.1158/1541-7786.MCR-23-0411
5.Büyüktiryaki, S. (2025). Sensitive and selective detection of cancer biomarkers with molecularly imprinted biosensors. In Talanta Open. https://doi.org/10.1016/j.talo.2025.100444
6.Cao, W., Qin, K., Li, F., & Chen, W. (2024). Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN). Journal of the National Cancer Center. https://doi.org/10.1016/j.jncc.2024.05.001
7.Carbone, A. (2020). Cancer classification at the crossroads. Cancers. https://doi.org/10.3390/cancers12040980
8.Chen, X., Gole, J., Gore, A., He, Q., Lu, M., Min, J., Yuan, Z., Yang, X., Jiang, Y., Zhang, T., Suo, C., Li, X., Cheng, L., Zhang, Z., Niu, H., Li, Z., Xie, Z., Shi, H., Zhang, X., … Jin, L. (2020). Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nature Communications, 11(1), 3475. https://doi.org/10.1038/s41467-020-17316-z
9.Crook, T., Leonard, R., Mokbel, K., Thompson, A., Michell, M., Page, R., Vaid, A., Mehrotra, R., Ranade, A., Limaye, S., Patil, D., Akolkar, D., Datta, V., Fulmali, P., Apurwa, S., Schuster, S., Srinivasan, A., & Datar, R. (2022). Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers. https://doi.org/10.3390/cancers14143341
10.Crosby, D., Bhatia, S., Brindle, K. M., Coussens, L. M., Dive, C., Emberton, M., Esener, S., Fitzgerald, R. C., Gambhir, S. S., Kuhn, P., Rebbeck, T. R., & Balasubramanian, S. (2022). Early detection of cancer. Science, 375(6586). https://doi.org/10.1126/science.aay9040
11.Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2024). Biomarkers in Cancer Detection, Diagnosis, and Prognosis. In Sensors. https://doi.org/10.3390/s24010037
12.Di Stasio, D., Montella, M., Romano, A., Colella, G., Serpico, R., & Lucchese, A. (2022). High-Definition Ultrasound Characterization of Squamous Carcinoma of the Tongue: A Descriptive Observational Study. Cancers, 14(3), 564. https://doi.org/10.3390/cancers14030564
13.Gao, Q., Zeng, Q., Wang, Z., Li, C., Xu, Y., Cui, P., Zhu, X., Lu, H., Wang, G., Cai, S., Wang, J., & Fan, J. (2022). Circulating cell-free DNA for cancer early detection. The Innovation, 3(4), 100259. https://doi.org/10.1016/j.xinn.2022.100259
14.Global cancer burden growing, amidst mounting need for services. (2024). In Saudi Medical Journal.
15.Guo, W., Chen, X., Liu, R., Liang, N., Ma, Q., Bao, H., Xu, X., Wu, X., Yang, S., Shao, Y., Tan, F., Xue, Q., Gao, S., & He, J. (2022). Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine. https://doi.org/10.1016/j.ebiom.2022.104131
16.Jiang, K., Dai, Z., Chen, J., Gao, Z., Tong, H., Liu, H., Huang, G., Liu, F., Ma, Y., Pan, E., Yin, J., Yao, L., & Wang, L. (2025). Evaluating sensitivity of NGS-based mutation detection across diverse sample types in prostate cancer. Diagnostic Pathology . https://doi.org/10.1186/s13000-025-01697-0
17.Kim, S. Y., Jeong, S., Lee, W., Jeon, Y., Kim, Y. J., Park, S., Lee, D., Go, D., Song, S. H., Lee, S., Woo, H. G., Yoon, J. K., Park, Y. S., Kim, Y. T., Lee, S. H., Kim, K. H., Lim, Y., Kim, J. S., Kim, H. P., … Kim, T. Y. (2023). Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection. Experimental and Molecular Medicine. https://doi.org/10.1038/s12276-023-01119-5
18.Kisiel, J. B., Papadopoulos, N., Liu, M. C., Crosby, D., Srivastava, S., & Hawk, E. T. (2022). Multicancer early detection test: Preclinical, translational, and clinical evidence–generation plan and provocative questions. Cancer, 128(S4), 861–874. https://doi.org/10.1002/cncr.33912
19.Klein, E. A., Richards, D., Cohn, A., Tummala, M., Lapham, R., Cosgrove, D., Chung, G., Clement, J., Gao, J., Hunkapiller, N., Jamshidi, A., Kurtzman, K. N., Seiden, M. V., Swanton, C., & Liu, M. C. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology. https://doi.org/10.1016/j.annonc.2021.05.806
20.Lescuyer, G., Harlé, A., Kumar, H. S., Constantoulakis, P., Pfarr, N., Heitzer, E., Michon, C., Russo, G., Speel, E. J. M., Piecyk, M., Husson, M., Christopoulou, G., Mayr, E. M., Koppermann, M. L., Passot, C., Graf, R., Aoul, A. H., Bourdon, V., Dubbink, H. J., … Payen, L. (2025). Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing. Journal of Molecular Diagnostics. https://doi.org/10.1016/j.jmoldx.2025.08.008
21.Liao, L. (2025). Inequality in breast cancer: Global statistics from 2022 to 2050. Breast. https://doi.org/10.1016/j.breast.2024.103851
22.Lin, C., Liu, X., Zheng, B., Ke, R., & Tzeng, C. M. (2021). Liquid biopsy, ctDNA diagnosis through NGS. In Life. https://doi.org/10.3390/life11090890
23.Liu, H., Zhang, J., & Lin, F. (2018). Lung and Mediastinum. In Handbook of Practical Fine Needle Aspiration and Small Tissue Biopsies (pp. 243–301). Springer International Publishing. https://doi.org/10.1007/978-3-319-57386-1_6
24.Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., & Wei, J. (2024). Liquid biopsy in cancer current: status, challenges and future prospects. In Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-02021-w
25.McCart Reed, A. E., Kalinowski, L., Simpson, P. T., & Lakhani, S. R. (2021). Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. In Breast Cancer Research. https://doi.org/10.1186/s13058-020-01384-6
26.Mehta, S., Shelling, A., Muthukaruppan, A., Lasham, A., Blenkiron, C., Laking, G., & Print, C. (2010). Predictive and prognostic molecular markers for cancer medicine. Therapeutic Advances in Medical Oncology, 2(2), 125–148. https://doi.org/10.1177/1758834009360519
27.Meridianbioscience. (2026). The Growing Demand for Personalized Diagnostics: Navigating the Benefits and Limits of qPCR vs. NGS. https://www.meridianbioscience.com/lifescience-blog/the-growing-demand-for-personalized-diagnostics-navigating-the-benefits-and-limits-of-qpcr-vs-ngs/
28.Morgan, E., Soerjomataram, I., Rumgay, H., Coleman, H. G., Thrift, A. P., Vignat, J., Laversanne, M., Ferlay, J., & Arnold, M. (2022). The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. https://doi.org/10.1053/j.gastro.2022.05.054
29.Naegele, S., Ruiz-Torres, D. A., Zhao, Y., Goss, D., & Faden, D. L. (2024). Comparing the Diagnostic Performance of Quantitative PCR, Digital Droplet PCR, and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus–Associated Cancers. Journal of Molecular Diagnostics. https://doi.org/10.1016/j.jmoldx.2023.11.007
30.Neefs, I., De Meulenaere, N., Vanpoucke, T., Vandenhoeck, J., Peeters, D., Peeters, M., Van Camp, G., & Op de Beeck, K. (2025). Simultaneous detection of eight cancer types using a multiplex droplet digital PCR assay. Molecular Oncology, 19(1), 188–203. https://doi.org/10.1002/1878-0261.13708
31.Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024). Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. In Cell. https://doi.org/10.1016/j.cell.2024.02.041
32.Rubinstein, W. S., Patriotis, C., Dickherber, A., Han, P. K. J., Katki, H. A., LeeVan, E., Pinsky, P. F., Prorok, P. C., Skarlupka, A. L., Temkin, S. M., Castle, P. E., & Minasian, L. M. (2024). Cancer screening with multicancer detection tests: A translational science review. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21833
33.Shao, S. H., Allen, B., Clement, J., Chung, G., Gao, J., Hubbell, E., Liu, M. C., Swanton, C., Tang, W. H. W., Yimer, H., & Tummala, M. (2023). Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options. Tumori. https://doi.org/10.1177/03008916221133136
34.Sharma, R., & Khubchandani, J. (2024). Global, Regional, and National Burden of Tracheal, Bronchus, and Lung Cancer in 2022: Evidence from the GLOBOCAN Study. Epidemiologia. https://doi.org/10.3390/epidemiologia5040053
35.Shi, H., Zhang, W., Zhang, L., Zheng, Y., & Dong, T. (2023). Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis. In Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1265202
36.Silva, T. F. da, Azevedo, J. C. de, Teixeira, E. B., Casseb, S. M. M., Moreira, F. C., Assumpção, P. P. de, Santos, S. E. B. dos, & Calcagno, D. Q. (2024). From haystack to high precision: advanced sequencing methods to unraveling circulating tumor DNA mutations. In Frontiers in Molecular Biosciences. https://doi.org/10.3389/fmolb.2024.1423470
37.Sinha, T. (2018). Tumors: Benign and Malignant. Cancer Therapy & Oncology International Journal. https://doi.org/10.19080/ctoij.2018.10.555790
38.Su, W. C., Tsai, Y. C., Tsai, H. L., Chang, T. K., Yin, T. C., Huang, C. W., Chen, Y. C., Li, C. C., Chen, P. J., Liu, Y. R., Hsieh, T. H., & Wang, J. Y. (2022). Comparison of Next‐Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment‐Related Genomic Status in Patients with Metastatic Colorectal Cancer. Current Issues in Molecular Biology. https://doi.org/10.3390/cimb44040106
39.Suster, D., & Suster, S. (2025). Large Cell Neuroendocrine Carcinoma of the Lung: In Search for a Better Definition. In Advances in Anatomic Pathology. https://doi.org/10.1097/PAP.0000000000000504
40.Tappia, P. S., & Ramjiawan, B. (2023). Biomarkers for Early Detection of Cancer: Molecular Aspects. International Journal of Molecular Sciences, 24(6), 5272. https://doi.org/10.3390/ijms24065272
41.Tenchov, R., Sapra, A. K., Sasso, J., Ralhan, K., Tummala, A., Azoulay, N., & Zhou, Q. A. (2024). Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers. In ACS Pharmacology and Translational Science. https://doi.org/10.1021/acsptsci.3c00346
42.Thomas, D. S., Chai, J., & Lu, Y. J. (2025). The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection. In Exploration of Targeted Anti-tumor Therapy. https://doi.org/10.37349/etat.2025.1002314
43.Xia, C., Dong, X., Li, H., Cao, M., Sun, D., He, S., Yang, F., Yan, X., Zhang, S., Li, N., & Chen, W. (2022). Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chinese Medical Journal. https://doi.org/10.1097/CM9.0000000000002108
44.Zafar, S., Hafeez, A., Shah, H., Mutiullah, I., Ali, A., Khan, K., Figueroa-González, G., Reyes-Hernández, O. D., Quintas-Granados, L. I., Peña-Corona, S. I., Kiyekbayeva, L. N., Butnariu, M., Tota, C.-E., Caunii, A., Büsselberg, D., Sharifi-Rad, J., & Leyva-Gómez, G. (2025). Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives. European Journal of Medical Research. https://doi.org/10.1186/s40001-025-03003-6
45.Zamani, R., & Rezaei, N. (2024). Immune-scoring in head and neck squamous cell carcinoma: a scoping review. Expert Review of Clinical Immunology, 20(8), 1009–1017. https://doi.org/10.1080/1744666X.2023.2262140
46.Zhao, Y., Gulati, R., Lange, J., Olivas-Martinez, A., Raoof, S., Zheng, Y., Feng, Z., & Etzioni, R. (2025). Sensitivity Measures in Studies of Cancer Early Detection Biomarkers. Cancer Epidemiology Biomarkers and Prevention. https://doi.org/10.1158/1055-9965.EPI-24-1849
47.Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024). Tumor biomarkers for diagnosis, prognosis and targeted therapy. In Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-01823-2
48.Zhu, B., Gu, H., Mao, Z., Beeraka, N. M., Zhao, X., Anand, M. P., Zheng, Y., Zhao, R., Li, S., Manogaran, P., Fan, R., Nikolenko, V. N., Wen, H., Basappa, B., & Liu, J. (2024). Global burden of gynaecological cancers in 2022 and projections to 2050. Journal of Global Health. https://doi.org/10.7189/JOGH.14.04155
